<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561963</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-CP-025</org_study_id>
    <nct_id>NCT01561963</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast</brief_title>
  <official_title>A Phase 1, Open-label, Three-period, Fixed-sequence Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how the pharmacokinetics of apremilast may be
      affected by a single intravenous dose of rifampin and multiple oral doses of rifampin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic measures: area under the plasma concentration-time curve</measure>
    <time_frame>Up to 2 days post dose</time_frame>
    <description>Pharmacokinetic measures: area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic measures: area under the maximum observed plasma concentration</measure>
    <time_frame>Up to 2 days post dose</time_frame>
    <description>Pharmacokinetic measures: area under the maximum observed plasma concentration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Apremilast and Rifampin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 30 mg apremilast on Day 1 in Period 1;
A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;
Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>Each subject will receive the following 3 treatments in the same fixed sequence during the study (the study days are numbered sequentially across all 3 periods):
A single oral dose of 30 mg apremilast on Day 1 in Period 1;
A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;
Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3.</description>
    <arm_group_label>Apremilast and Rifampin</arm_group_label>
    <other_name>CC-10004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;
Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3.</description>
    <arm_group_label>Apremilast and Rifampin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects of any ethnic origin between ages of 18 and 55 with a
             body mass index between 18 and 33

        Exclusion Criteria:

          -  Recent history (i.e., within 3 years) of any clinically significant neurological,
             gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, endocrine,
             hematological, dermatological, psychological, allergic or other major disorders.

          -  Use of any prescribed or non-prescribed systemic or topical medication (including
             vitamins and herbal medicines, e.g. St. John's Wort) within 30 days of the first dose,
             unless an exception is granted by the sponsor.

          -  Presence of any surgical or medical conditions possibly affecting drug absorption,
             distribution, metabolism, and excretion, or plans to have elective or medical
             procedures during the conduct of the trial.

          -  Exposure to an investigational drug (new chemical entity) within 30 days prior to the
             first dose administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Palmisano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Liu Y, Zhou S, Wan Y, Wu A, Palmisano M. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. Br J Clin Pharmacol. 2014 Nov;78(5):1050-7. doi: 10.1111/bcp.12448.</citation>
    <PMID>24962564</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2012</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apremilast</keyword>
  <keyword>drug interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

